Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWS WIRES REGINA, Saskatchewan, May 16, 2022 (GLOBE NEWSWIRE) -- Proton Capital Corp. (TSXV: PTN) (the “Corporation”) is pleased to...
CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its second quarter ended December 31, 2009. Palatin reported net income...
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of...
CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440...
CRANBURY, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its quarter ended September 30, 2009. Palatin reported a net loss of...
CRANBURY, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2010 financial results on Monday, November 16, 2009...
CRANBURY, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 2009 BIO Investor Forum on Thursday, October 29, 2009 at...
CRANBURY, N.J., Sept. 29 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it will receive $5 million from AstraZeneca relating to an amendment of its...
CRANBURY, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will...
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| 156 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| 260 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
